Insider Selling: Fulcrum Therapeutics (NASDAQ:FULC) Director Sells $178,050.00 in Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Robert Gould sold 15,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the transaction, the director owned 469,864 shares in the company, valued at $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Fulcrum Therapeutics Price Performance

FULC stock opened at $10.11 on Friday. The firm has a market cap of $547.13 million, a price-to-earnings ratio of -8.57 and a beta of 3.20. Fulcrum Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $15.74. The firm has a fifty day moving average price of $10.67 and a two-hundred day moving average price of $8.73.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Cantor Fitzgerald increased their price target on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. The Goldman Sachs Group reaffirmed a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, Stifel Nicolaus set a $25.00 price objective on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Fulcrum Therapeutics has an average rating of “Hold” and a consensus target price of $19.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of Fulcrum Therapeutics by 186.1% during the first quarter. Invesco Ltd. now owns 85,767 shares of the company’s stock valued at $247,000 after purchasing an additional 55,791 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Fulcrum Therapeutics during the 1st quarter valued at about $164,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth about $425,000. Exome Asset Management LLC raised its position in shares of Fulcrum Therapeutics by 143.0% during the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after buying an additional 405,538 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Fulcrum Therapeutics by 62.1% in the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after acquiring an additional 45,157 shares during the period. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.